

# Target attainment of ciprofloxacin as infection prophylaxis during chemotherapy-induced neutropenia in patients treated for haematological malignancies.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON20490

### Source

Nationaal Trial Register

### Brief title

TBA

### Health condition

All patients receiving ciprofloxacin prophylaxis as standard care will be included, regardless of treatment with different cytostatic agents, regardless of the severity of adverse effects of the treatment (in particular mucositis) and regardless of the degree and duration of neutropenia, as long as ciprofloxacin is recommended as infection prophylaxis within the applied treatment protocol.

## Sponsors and support

**Primary sponsor:** Amsterdam UMC - location Academic Medical Centre (AMC), University of Amsterdam

**Source(s) of monetary or material Support:** Amsterdam UMC - location Academic Medical Centre (AMC), University of Amsterdam

## Intervention

## Outcome measures

### Primary outcome

AUC<sub>0-24</sub>/MIC  $\geq 125$ , in which all relevant commensal Gram-negative bacteria of the intestinal tract will be taken into account.

### Secondary outcome

C<sub>max</sub>/MIC  $\geq 8$ , and fAUC<sub>0-24</sub>/MIC  $\geq 90$  based on an average unbound fraction of ciprofloxacin of 70% and analyze the frequency of positive cultures with ciprofloxacin-resistant organisms or ESBL-producing Gram-negative bacteria in patients treated for haematological malignancies.

## Study description

### Background summary

Prospectively investigate whether ciprofloxacin, administered as antibiotic prophylaxis in patients treated for haematological malignancies (with or without gastrointestinal mucositis), in the currently recommended dosing regimen (500mg orally twice a day, 400mg intravenously twice a day or another dose, which is adjusted to renal function), results in the PK/PD target attainment defined as AUC<sub>0-24</sub>/MIC  $\geq 125$ .

### Study objective

Exploratory study investigating the efficacy of the currently recommended dosing regimen of ciprofloxacin prophylaxis in patients treated for haematological malignancies.

### Study design

Four venapunctures in a time period of 48 hours and one questionnaire about the frequency and consistency of the stools.

### Intervention

No intervention in patient's 'treatment' is made, intervention consists of four venapunctures in a time period of 48 hours, obtaining a maximum of 12 ml of blood in total and one questionnaire about the frequency and consistency of the stools.

## Contacts

### Public

Amsterdam UMC, location Academic Medical Centre (AMC), University of Amsterdam  
Suzanne L. de Vroom

0031 (0)6 29189028

### Scientific

Amsterdam UMC, location Academic Medical Centre (AMC), University of Amsterdam  
Suzanne L. de Vroom

0031 (0)6 29189028

## Eligibility criteria

### Inclusion criteria

Hospitalized adult patients (age  $\geq 18$  years) receiving ciprofloxacin as infection prophylaxis as part of standard care prescribed by the treating physician.

### Exclusion criteria

Four patient-groups will be excluded as they are known to exhibit altered pharmacokinetics of antibiotics: patients in the intensive care unit (ICU), all patients receiving renal replacement therapy (RRT), patients with cystic fibrosis (CF) and severely burned patients.

## Study design

### Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

## Recruitment

NL  
Recruitment status: Recruiting  
Start date (anticipated): 12-02-2019  
Enrollment: 46  
Type: Anticipated

## IPD sharing statement

**Plan to share IPD:** Undecided

## Ethics review

Positive opinion  
Date: 12-02-2019  
Application type: First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL7520
Other	METC AMC : METC 2018_290

## Study results